Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES BELLBOX IN CONJUNCTION WITH MERGER WITH LYKO
Mandate

VINGE ADVISES BELLBOX IN CONJUNCTION WITH MERGER WITH LYKO

November 26, 2014

Vinge has advised Bellbox in conjunction with the merger with Lyko. The merger has created a Nordic region leader within professional haircare and beauty products. The combined group is expected to have a turnover of approximately SEK 500 million and the merger has created a multi-channel retailer with Bellbox’s store network, which consists of 30 wholly owned stores in Sweden and Norway, and Lyko.se, a destination for beauty products online.

Vinge’s team consisted of responsible partner Jonas Bergström together with, among others, associates Alex Miler and Maria Dahlin. Louise Brorson Salomon provided financing advice.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025